1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsExploratory Cancer Immunology Projects and Technologies (ExCITe) is sponsored by National Cancer Institute (NCI). Supports innovative, high-risk/high-reward research projects that test novel hypotheses or develop novel technologies to advance understanding of cancer immunology.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | Research Funding National Institutes of Health Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) Through this Notice of Special Interest (NOSI) on Exploratory Cancer Immunology Projects and Technologies (ExCITe), the National Cancer Institute intends to encourage R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology.
Research projects should focus on fundamental areas of cancer immunology, including innate and adaptive immune responses, tumor-immune ecosystems and their dynamic interactions, the immune response to metastases, systemic immune networks, immunosurveillance, tumor immune evasion, or immunomodulation. Projects should be distinct in scope and focus from those supported through the traditional R01 mechanism.
ExCITe studies may involve considerable risk but have the potential to lead to research breakthroughs or the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in cancer immunology and cancer immunotherapy research.
R21 applications submitted through the ExCITe NOSI should propose innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. Applicants should propose research studies to address fundamental aspects in the field of tumor immunology and/or innovative ways to enhance anti-cancer immunity.
Innovative approaches that target both primary tumor and metastases are encouraged. Establishing new or improved in vivo/in vitro models to study the dynamics of tumor-immune ecosystems are also encouraged. This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026.
Medical - Clinical Science
According to the current listing, eligibility includes: Universities, Nonprofits, State/local governments. Confirm the full requirements in the official notice before applying.
Exploratory Cancer Immunology Projects and Technologies (ExCITe) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article